Dataset from A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID When Administered to HIV-1 Infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of GW433908 BID Administered to PI-Naïve, Pediatric Subjects 2 to < 6 Years Old

This is a 48-week study to collect information on the safety and activity of an
investigational medicine in patients, ages 2 to 18 years old, with HIV infection .

本研究为一项为期48周的临床研究，旨在收集2至18岁人类免疫缺陷病毒（HIV）感染患者使用某试验性药物（investigational medicine）的安全性与药效活性相关信息。